Overview

A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma

Status:
Not yet recruiting
Trial end date:
2024-11-15
Target enrollment:
Participant gender:
Summary
This study evaluates the safety, tolerability, PK, and preliminary efficacy of AZD0466 as monotherapy or in combination with other anticancer agents in patients with advanced NHL
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
AstraZeneca